Zai Lab Ltd (ZLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zai Lab Ltd (ZLAB) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.91 Million) by net assets ($661.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zai Lab Ltd balance sheet quality to measure how much of total assets are equity-financed.
Zai Lab Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Zai Lab Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Zai Lab Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Zai Lab Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zai Lab Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gränges AB (publ)
ST:GRNG
|
-0.026x |
|
Simplo Technology Co Ltd
TWO:6121
|
0.027x |
|
UCloud Technology Co Ltd
SHG:688158
|
0.024x |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
N/A |
|
HENSOLDT AG UNSP. ADS
F:HAG0
|
N/A |
|
Chow Tai Seng Jewellery Co Ltd
SHE:002867
|
0.026x |
|
Innodata Inc
NASDAQ:INOD
|
0.291x |
|
HORNBACH Baumarkt AG
HM:HBM
|
0.043x |
Annual Cash Flow Conversion Efficiency for Zai Lab Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Zai Lab Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see ZLAB stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $715.50 Million | $-150.79 Million | -0.211x | +17.52% |
| 2024-12-31 | $840.90 Million | $-214.87 Million | -0.256x | -2.65% |
| 2023-12-31 | $796.12 Million | $-198.18 Million | -0.249x | +29.20% |
| 2022-12-31 | $1.05 Billion | $-367.64 Million | -0.352x | +11.66% |
| 2021-12-31 | $1.38 Billion | $-549.23 Million | -0.398x | -115.41% |
| 2020-12-31 | $1.17 Billion | $-216.06 Million | -0.185x | +71.50% |
| 2019-12-31 | $294.66 Million | $-191.01 Million | -0.648x | -66.87% |
| 2018-12-31 | $251.08 Million | $-97.54 Million | -0.388x | -182.25% |
| 2017-12-31 | $235.17 Million | $-32.37 Million | -0.138x | -122.06% |
| 2016-12-31 | $-51.55 Million | $-32.16 Million | 0.624x | -0.05% |
| 2015-12-31 | $-18.37 Million | $-11.46 Million | 0.624x | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more